Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC)
McGahan L
Record ID 32017000330
English
Authors' recommendations:
There is no evidence regarding quality of life, patient reported outcome measures or patient reported experience measures to determine whether atezolizumab provides clinically significant improvement in the symptoms or severity of NSCLC. Results from the OAK (phase III) randomized, open-label trial hold limited external validity as participants are not entirely generalisable to clinical practice. Longer trials are needed which directly compare the safety and efficacy of atezolizumab versus other immunotherapies such as nivolumab or pembrolizumab, or docetaxel in combination with nintedanib or ramucirumab.
Details
Project Status:
Completed
URL for project:
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en
Year Published:
2017
URL for published report:
http://eprints.hta.lbg.ac.at/1120/1/DSD_HSO_Nr.68.pdf
URL for additional information:
http://eprints.hta.lbg.ac.at/1120/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Immune Checkpoint Inhibitors
- Carcinoma, Non-Small-Cell Lung
- Antibodies, Monoclonal, Humanized
- Lung Neoplasms
- Antineoplastic Agents, Immunological
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.